3 results
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Primary objective: To assess the mean difference in time spent in the euglycemic range (interstitial glucose >3.9-<10.0 mmol/L), expressed as hours/day, between the two 16-week intervention periods, i.e. RT-CGM versus masked CGM, in…
To explore the safety and feasibility of continuous and intermittent hypoxia therapy in PD and the differences of symptom modification of different hypoxia protocols. Secondary outcomes include exploring the responsiveness of subjective and…